Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies

Area of Science:

• Hematology
• Immunology
• Analytical Chemistry

Background:

• Minimal residual disease (MRD) quantification is crucial for prognosis in mature B-cell malignancies.
• Flow cytometry has emerged as a preferred method for MRD detection in certain lymphomas due to technological advancements and standardization.

Purpose of the Study:

• To describe general aspects of flow cytometric standardization for MRD detection.
• To illustrate technical standardization using chronic lymphocytic leukemia and multiple myeloma as examples.
• To highlight next-generation flow (NGF) for MRD data acquisition and analysis in multiple myeloma.

Main Methods:

• Utilizing benchtop cytometers capable of analyzing ≥4 colors.
• Implementing standardized flow cytometry protocols based on EuroFlow strategies.
• Employing a novel approach, next-generation flow (NGF), for data acquisition and analysis.

Main Results:

• Standardization of flow cytometry enables reliable MRD quantification.
• EuroFlow strategies provide a framework for consistent MRD detection.
• NGF offers advanced capabilities for MRD analysis in multiple myeloma.

Conclusions:

• Standardized flow cytometry is essential for accurate MRD assessment in B-cell malignancies.
• The described methods facilitate prognostic evaluation through precise MRD detection.
• Next-generation flow represents a significant advancement in MRD analysis for multiple myeloma.